Abstract: This invention relates to a process for the recovery of precious metal/s from a precious metal-containing material in an aqueous leach slurry or solution. The process includes the step of contacting the precious metal/s in the leach slurry or solution with a ligand selected from dithiooxamide (rubeanic acid), or a substituted dithiooxamide. The leaching of PGMs, gold and silver from their ores using the ligand of the present invention may take place under aqueous alkaline conditions, avoiding both corrosive acidic conditions and the use of cyanide.

Abstract: An object of the present invention is to provide an industrially suitable process for preparing an imidazolidin-2,4-dione compound which is safe, simple and easy to prepare the imidazolidin-2,4-dione compound with high yield, which is a useful compound, for example, as a material for decomposing a harmful halogenated aromatic hydrocarbon compound such as dioxin, etc., an electroless silver plating solution for electronic parts, or a diazo copying material, etc. This object can be solved by a process for preparing an imidazolidin-2,4-dione compound which comprises subjecting a 4,5-dihydroxy-2-imidazolidinone compound, (1) to dehydration reaction in the presence of an acid catalyst(s); or (2) to reaction at 100 to 300° C. Or, it can be solved by a process for preparing an imidazolidin-2,4-dione compound which comprises reacting a mixed solution of a urea compound, glyoxal, and a base at 20 to 300° C.

Abstract: Conventional I-form crystals of 5-hydroxy-1-methylhydantoin contain, remaining therein in a considerable amount, the organic solvent used in a purification step. In contrast, in II-form crystals, the amount of the organic solvent remaining therein is smaller than the detection limit. Namely, the II-form crystals contain substantially no residual organic solvent. The novel II-form crystals of 5-hydroxy-1-methylhydantoin obtained through recrystallization from water not only contain substantially no residual organic solvent, but also have a high bulk density and are hence advantageous for pharmaceutical preparation. They further have properties advantageous for production, such as low adhesion. The crystals are significantly useful as a material for medicines required to have high safety, such as drugs for renal insufficiency.

Abstract: Conventional I-form crystals of 5-hydroxy-1-methylhydantoin contain, remaining therein in a considerable amount, the organic solvent used in a purification step. In contrast, in II-form crystals, the amount of the organic solvent remaining therein is smaller than the detection limit. Namely, the II-form crystals contain substantially no residual organic solvent. The novel II-form crystals of 5-hydroxy-1-methylhydantoin obtained through recrystallization from water not only contain substantially no residual organic solvent, but also have a high bulk density and are hence advantageous for pharmaceutical preparation. They further have properties advantageous for production, such as low adhesion. The crystals are significantly useful as a material for medicines required to have high safety, such as drugs for renal insufficiency.

Abstract: Conventional I-form crystals of 5-hydroxy-1-methylhydantoin contain, remaining therein in a considerable amount, the organic solvent used in a purification step. In contrast, in II-form crystals, the amount of the organic solvent remaining therein is smaller than the detection limit. Namely, the II-form crystals contain substantially no residual organic solvent. The novel II-form crystals of 5-hydroxy-1-methylhydantoin obtained through recrystallization from water not only contain substantially no residual organic solvent, but also have a high bulk density and are hence advantageous for pharmaceutical preparation. They further have properties advantageous for production, such as low adhesion. The crystals are significantly useful as a material for medicines required to have high safety, such as drugs for renal insufficiency.

Abstract: A polymer that includes at least one monomeric unit having a pendant substituent group according to formula (II): wherein: R1 is H, chloro, bromo, alkyl, hydroxyalkyl, aryl, or aralkyl, R2 and R3 are each independently H, alkyl, hydroxyalkyl, aryl, aralkyl, uriedo, or carboxyalkylene, R4 is alkylene or R5, R7, and R10 are each independently alkylene, R6, R8, and R9 are each independently H or alkyl, A is O or N—R11, provided if A is O and R4 is methylene, then R1 cannot be H, chloro, or bromo, R11 is H or alkyl, and X? is an anion, is useful in personal care application, such as hair styling compositions.

Abstract: Antiatherosclerotic compounds of Formula I are provided: wherein: R is lower alkyl, alkenyl, alkynyl, or —O—(CH2)n—COOR?; R? is lower alkyl; n is an integer of 1–3; Ar is phenyl, or phenyl substituted with one or more of halogen, lower alkyl, alkenyl, alkynyl, alkoxy, perfluoroalkyl, perfluoroalkoxy, or alkylthio; and pharmaceutically acceptable salts thereof.

Abstract: Compounds of Formula I are provided: wherein: R is lower alkyl or branched lower alkyl; and Ar is phenyl, phenyl substituted with one or more of halogen, lower alkyl, lower alkoxy, lower alkylthio, lower alkylamino, cyano, or perfluoroalkoxy, or a heteroaromatic moiety; and pharmaceutically acceptable salts thereof.

Abstract: The invention relates to a novel class of aminobenzophenones derivatives, to pharmaceutical preparations comprising said compounds, to dosage units of such preparations, to methods of treating patients comprising administering said compounds, and to the use of said compounds in the manufacture of pharmaceutical preparations.

Abstract: Matrix metalloprotease inhibiting compounds, pharmaceutical compositions thereof and a method of disease treatment using such compounds are presented.

Abstract: Compounds of Formula I are provided: 1

Abstract: Antiatherosclerotic compounds of Formula I are provided: 1

Abstract: A remover composition obtained by adding 1 to 90% by weight of a cyclic urea compound represented by the following general formula (I): wherein, each of R1 and R2 independently represents a hydrogen atom, hydroxyl group, carboxyl group or alkyl group which may be substituted, and Z represents an oxygen atom or sulfur atom.

Abstract: A process for preparing specific 1-substituted 5-hydroxy-imidazoline-2,4-diones by reacting glyoxylic acid with N-substituted ureas is provided, where this process is carried out in a 10-80% strength aqueous solution and in the presence of an acid catalyst. The 1-substituted 5-hydroxy-imidazoline-2,4-diones can subsequently be converted in a further reaction step to give 1-substituted 5-alkoxy-imidazoline-2,4-diones.

Abstract: A process for preparing a halohydrin of a water-miscible olefin comprising: reacting a water-miscible olefin in water with a compound of the formula (I) wherein R1 and R2 independently represent a branched or unbranched, substituted or unsubstituted, lower alkyl having from 1 to 5 carbons and X is a halogen, to thereby form the halohydrin of the water-miscible olefin.

Abstract: Acyl imidazolidinones and compositions containing the same are disclosed, which are particularly suitable for use as self-crosslinkers and can also be used as wet adhesion properties, especially in latex-based polymer systems. Processes for preparing such compounds, compositions containing the same, as well as additional uses thereof are also disclosed.

Abstract: Inhibitors for matrix metalloproteases, pharmaceutical compositions containing them, and a process for using them to treat a variety of physiological conditions. The compounds of the invention have the generalized formula (T)xA—B—D—E—G wherein A is an aryl or heteroaryl rings; B is an aryl or heteroaryl ring or a bond; each T is a substituent group; x is 0, 1, or 2; the group D represents the group E represents a two or three carbon chain bearing one to three substituent groups which are independent or are involved in ring formation, possible structures being shown in the text and claims; and the group G represents and with the proviso that when G is each of the substituents on E is an independent substituent; and include pharmaceutically acceptable salts thereof.

Abstract: Described is a process for preparing mixtures of mixed-alkylated methylolated 4,5-dihydroxyimidazolidin-2-ones by reaction of methylolated 4,5-dihydroxyimidazolidin-2-one (DMDHEU) with a monohydric C1-5 alcohol and a polyol selected from the group consisting of ethylene glycol, diethylene glycol, 1,2-propylene glycol, 1,3-propylene glycol, 1,2-butylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, glycerol and polyethylene glycols of the formula HO(CH2CH2O)nH where 3≦n≦20, the monohydric C1-5 alcohol and the polyol each being used in an amount of from 0.1 to 2.0 mol equivalents, based on DMDHEU, and the reaction being carried out at temperatures from 20° C. to 70° C. and at a pH of from 1 to 2.5, and the pH being set to a value of from 4 to 8 after the reaction.